5 月 13 日,药物临床试验登记与信息公示平台官网显示,百济神州登记了一项在既往接受过共价 BTK 抑制剂的复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤(CLL/SLL)患者中比较 BGB-16673 与研究者选择的治疗的 III 期研究。截图来源:药物临床试验登记与信息公示平台官网这是一项 III期、开放性、随机研究,旨在评价 BGB-16673 对比研究者选择的苯达莫司汀联合利妥昔单抗(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.